Combination treatment with NF-κB and BCL-2 inhibitors, such as navitoclax, showed synergistic anti-tumor activity, suggesting that NF-κB inhibition may be most effective within a rationally designed combination strategy [119]. This evidence concerns the gene NFKB1 and neoplasm.